Epidemiological aspects of central serous chorioretinopathy

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


Aim. To analyze the incidence of central serous chorioretinopathy among the Kazan’s population between 2009 and 2018.

Methods. A descriptive epidemiological study of the incidence of Central serous chorioretinopathy of the population of Kazan between 2009 and 2018 was conducted. It included an analysis of long-term changes in the incidence of male and female population and an assessment of the structure of morbidity by sex for the entire period and in dynamics. Testing for differences was performed using the nonparametric Mann–Whitney U test and Chi-square test with Yates correction.

Results. 831 new cases of central serous chorioretinopathy were registered in Kazan during 2009–2018, the ratio of men and women was approximately 1:1. In the dynamics of morbidity, the proportion of men increased from 24.2% in 2009 to 60.7% in 2018 (р=0.000002), while the proportion of women decreased from 75.8% in 2009 to 39.3% in 2018 (р=0.000002). The long-term dynamics for 2009–2018 is characterized by a statistically significant increase in the incidence rate of central serous chorioretinopathy in men (p=0.004) from 3.2 per 100 000 in 2009 to 14.8 per 100 000 in 2018. During the study period, the incidence rate in women remains at the same level, varying from 5.4 per 100 000 to 8 per 100 000 (p=0.663). Men are more likely to have central serous chorioretinopathy at a younger age (р=0.0001). The median age at the time of diagnosis in women was 55 years (Q25–Q75 45–65 years), in men — 45 years (Q25–Q75 37–56 years).

Conclusion. From 2009 to 2018, the incidence rate of central serous chorioretinopathy among men in Kazan significantly increased in both intensive (p=0.004) and extensive indicators (p=0.000002); сentral serous chorioretinopathy in men develops at an earlier age compared with women (median age of women at the time of diagnosis was 55 years, median age of men — 45 years, p=0.0001).


Full Text

Restricted Access

About the authors

D R Agliullin

Kazan State Medical University

Author for correspondence.
Email: dr.agliullin@gmail.com
ORCID iD: 0000-0001-7474-609X
SPIN-code: 1356-0270

Russian Federation, Kazan, Russia

G R Khasanova

Kazan State Medical University

Email: gulshatra@mail.ru
ORCID iD: 0000-0002-1733-2576
SPIN-code: 6704-2840

Russian Federation, Kazan, Russia

E A Abdulaeva

Kazan State Medical Academy

Email: abd@inbox.ru
ORCID iD: 0000-0003-3538-9354
SPIN-code: 9611-1344

Russian Federation, Kazan, Russia

S T Agliullina

Kazan State Medical University

Email: saida.agliullina@kazangmu.ru
ORCID iD: 0000-0003-4733-6911
SPIN-code: 2079-1833

Russian Federation, Kazan, Russia

A N Amirov

Kazan State Medical Academy

Email: ksma.rf@tatar.ru
SPIN-code: 7833-9650

Russian Federation, Kazan, Russia

A N Kuskov

Republican Clinical Ophthalmological Hospital named after Professor E.V. Adamuk

Email: zorg3128@gmail.com

Russian Federation, Kazan, Russia

A A Kim

Clinic “KORD”

Email: kim.alexey87@gmail.com

Russian Federation, Kazan, Russia

A Yu Rascheskov

Clinic “Eye-surgery Rascheskov”

Email: raskovclinic@mail.ru

Russian Federation, Kazan, Russia

D A Lipinskiy

Clinic “Third eye”

Email: 3eyes-clinic@mail.ru

Russian Federation, Kazan, Russia

References

  1. Gemenetzi M., De Salvo G., Lotery A.J. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye (Lond.). 2010; 24 (12): 1743–1756. doi: 10.1038/eye.2010.130.
  2. Wang M., Munch I.C., Hasler P.W., Prunte C., Lar­sen M. Central serous chorioretinopathy. Acta Ophthalmol. 2008; 86 (2): 126–145. doi: 10.1111/j.1600-0420.2007.00889.x.
  3. Khasanova G.R., Hakimov N.M., Аgliullin D.R., Abdulaeva E.A. Risk factors for central serous chorioretinopathy. Syste­matic review and meta-analysis. Meditsina. 2020; 8 (1): 102–124. (In Russ.) doi: 10.29234/2308-9113-2020-8-1-102-124.
  4. Liew G., Quin G., Gillies M., Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin. Experim. Ophthalmol. 2013; 41: 201–214. doi: 10.1111/j.1442-9071.2012.02848.x.
  5. Kitzmann A.S., Pulido J.S., Diehl N.N., Hodge D.O., Burke J.P. The incidence of central serous chorioretino­pathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology. 2008; 115: 169–173. doi: 10.1016/j.ophtha.2007.02.032.
  6. Tsai D.C., Chen S.J., Huang C.C. Epidemiology of ­idiopathic central serous chorioretinopathy in Taiwan, 2001–2006: a population-based study. PLoS One. 2013; 8 (6): е66858. doi: 10.1371/journal.pone.0066858.
  7. Savilov Ye.D., Astaf'yev V.A., Zhdanova S.N., Zarudnev Ye.A. Epidemiologicheskiy ana­liz: metody statisticheskoy obrabotki materiala. (Epidemiological analysis: methods of statistical processing of the material.) Novosibirsk: Nauka-Tsentr. 2011; 156 p. (In Russ.)
  8. Yildiz O., Seyrek M. Vasodilating mechanisms of testosterone. Exp. Clin. Endocrinol. Diabetes. 2007; 115 (1): 1–6. doi: 10.1055/s-2007-949657.
  9. Ahad M.A., Chua C.N., Evans N.M. Central serous chorioretinopathy associated with testosterone therapy. Eye. 2005; 20: 503–505. doi: 10.1038/sj.eye.6701905.
  10. Ciloglu E., Unal F., Dogan N.C. The relationship between the central serous chorioretinopathy, choroidal thickness, and serum hormone levels. Graefes Arch. Clin. Exp. Ophthalmol. 2018; 256 (6): 1111–1116. doi: 10.1007/s00417-018-3985-x.
  11. Haimovici R., Koh S., Gagnon D.R., Lehrfeld T., Wellik S. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology. 2004; 111: 244–249. doi: 10.1016/j.ophtha.2003.09.024.
  12. Chumbley L.C., Frank R.N. Central serous retino­pathy and pregnancy. Am. J. Ophthalmol. 1974; 77 (2): 158–160. doi: 10.1016/0002-9394(74)90667-9.
  13. Morikawa M., Cho K., Kojima T., Chiba K., Ishikawa S., Umazume T., Nakagawa K., Yamada T., Yamada T., Minakami H. Risk factors for central serous chorioretino­pathy in pregnant Japanese women. J. Obstet. Gynaecol. Res. 2017; 43 (5): 866–872. doi: 10.1111/jog.13289.
  14. Ersoz M.G., Arf S., Hocaoglu M., Sayman Muslubas I., Karacorlu M. Patient characteristics and risk factors for central serous chorioretinopathy: an analysis of 811 patients. Brit. J. Ophthalmol. 2019; 103 (6): 725–729. doi: 10.1136/bjophthalmol-2018-312431.
  15. Chatziralli I., Kabanarou S.A., Parikakis E., Chatzirallis A., Xirou T., Mitropoulos P. Risk factors for central serous chorioretinopathy: multivariate approach in a case-control study. Curr. Eye Res. 2017; 42 (7): 1069–1073. doi: 10.1080/02713683.2016.1276196.
  16. Conway M.D., Noble J.A., Peyman G.A. Central serous chorioretinopathy in postmenopausal women recei­ving exogenous testosterone. Retin. Cases Brief. Rep. 2017; 11 (2): 95–99. doi: 10.1097/ICB.0000000000000298.
  17. Аgliullin D.R., Khasanova G.R., Abdulaeva E.A., Agliullina S.T., Amirov A.N., Kuskov A.N., Kim A.A., Rascheskov A.Yu., Lipinskiy D.A. The incidence of central serous chorioretinopathy in the population of Kazan: Results of a retrospective epidemiological analysis for 2009–2018. Tikhookeanskiy meditsinskiy zhurnal. 2020; (3): 30–33. (In Russ.) doi: 10.34215/1609-1175-2020-3-30-33.

Supplementary files

Supplementary Files Action
1.
Рис. 1. Половая структура заболеваемости центральной серозной хориоретинопатией населения г. Казани за период 2009–2018 гг.

Download (31KB) Indexing metadata
2.
Рис. 2. Многолетняя динамика заболеваемости центральной серозной хориоретинопатией мужского населения г. Казани за 2009–2018 гг.

Download (28KB) Indexing metadata
3.
Рис. 3. Многолетняя динамика заболеваемости центральной серозной хориоретинопатией женского населения г. Казани за 2009–2018 гг.

Download (26KB) Indexing metadata

Statistics

Views

Abstract - 8

PDF (Russian) - 0

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions


© 2021 Agliullin D.R., Khasanova G.R., Abdulaeva E.A., Agliullina S.T., Amirov A.N., Kuskov A.N., Kim A.A., Rascheskov A.Y., Lipinskiy D.A.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.





This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies